Insiders who reported open-market trades in the last 12 months at the companies Camille L. Bedrosian files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jeff E. Knight - $3.79M in CRNX purchases and sales in the last 12 months
Joshua B. Cohen - $3.60M in AMLX purchases and sales in the last 12 months
Justin B. Klee - $3.59M in AMLX purchases and sales in the last 12 months
Gina Mazzariello - $1.05M in AMLX purchases and sales in the last 12 months
George M. Milne Jr. - $831K in AMLX purchases and sales in the last 12 months
Camille L. Bedrosian is a corporate insider, tracked as Chief Medical Officer of Amylyx Pharmaceuticals, Inc. (AMLX). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Camille L. Bedrosian submitted recently?
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Camille L. Bedrosian been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($756K) across all tracked filings.
Camille L. Bedrosian is Chief Medical Officer of Amylyx Pharmaceuticals, Inc. (AMLX). 10 SEC Form 4 filings on record going back to 2024, most recently on 14 September 2026. Most recent open-market trade: sold $69K of AMLX on 14 September 2026. Lifetime open-market sales: $756K.
Recent transactions
12
The latest 12 SEC Form 4 transactions reported by Camille L. Bedrosian.
InsiderAlpha's records for Camille L. Bedrosian go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
